This assertion is extracted from an article (Campregher et al., 2010), which puts in relation the activin A receptor type 2A gene to the colorectal cancer and describes a drug—that is, Mesalazine—that reduces mutations in transforming growth factor of the gene. This evidence concerns the gene ACVR2A and colorectal cancer.